John Kenneth Jenkins
Independent DirectorDr. John Kenneth Jenkins, M.D. served as Principal of Drug and Biological Products of Greenleaf Health, LLC since February 2017. Dr. Jenkins had been an Independent Director at Provention Bio, Inc. since August 2020 until April 27, 2023. Dr. Jenkins is Managing Member of John K. Jenkins Advisors, LLC. Dr. Jenkins has been Independent Director of Corbus Pharmaceuticals Holdings, Inc. since June 5, 2018. Dr. Jenkins leads a team of experts to assist clients with their drug development programs from the early stages of product development through to regulatory submission and post-approval requirements. Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency employees and 19 product review divisions. During that time, he oversaw the review of thousands of new drug applications and biological licensing applications as well as the approval of more than 400 new molecular entities. Dr. Jenkins also served as a member of the CDER Senior Leadership Team and was involved in broad policy initiatives, including negotiation and implementation of the Prescription Drug User Fee and biosimilar programs. Previously, Dr. Jenkins worked in various positions of increasing responsibility at FDA from May 1992 until his retirement in January 2017. Dr. Jenkins began his FDA career in 1992, where he was a medical officer in the Division of Oncology and Pulmonary Drug Products. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the Division of Pulmonary Drug Products in 1995. He became the Director of the Office of Drug Evaluation II in 1999 and remained in that position until he was appointed Director of OND in 2002. Following his retirement from FDA after over 25 years of Federal service in January 2017, Dr. Jenkins joined Greenleaf Health, an FDA-focused, strategic consulting firm where he serves as Principal, Drug and Biological Products. Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his post-graduate medical training in internal medicine, pulmonary diseases and critical care medicine at Virginia Commonwealth University/Medical College of Virginia in Richmond. Prior to joining FDA, Dr. Jenkins served as Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, Virginia.
Positions
- Company NameCorbus Pharmaceuticals Holdings, Inc.Stock CodeCRBPPositionIndependent DirectorColleagues
- YCYuval CohenCEO & Director
- RSRachelle Suzanne JacquesIndependent Chairman of the Board
- SFSean F. MoranChief Financial Officer
- IHIan HodgsonChief Operating Officer
- GSG. Scott GoekenGeneral Counsel & Corporate Secretary
- CBChristina BertschVice President of Human Resources
- AAAnne AltmeyerIndependent Director
- WKWinston KungIndependent Director
